Simon Mallal

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5763145/publications.pdf

Version: 2024-02-01

38742 18647 15,602 129 50 119 citations h-index g-index papers 136 136 136 17364 docs citations times ranked citing authors all docs

#	Article	IF	Citations
1	SARS-CoV-2 vaccination induces immunological T cell memory able to cross-recognize variants from Alpha to Omicron. Cell, 2022, 185, 847-859.e11.	28.9	590
2	Immunodominant MHC-II (Major Histocompatibility Complex II) Restricted Epitopes in Human Apolipoprotein B. Circulation Research, 2022, 131, 258-276.	4.5	8
3	Altered subgenomic RNA abundance provides unique insight into SARS-CoV-2 B.1.1.7/Alpha variant infections. Communications Biology, 2022, 5 , .	4.4	12
4	Deep Sequencing Analysis of Individual HIV-1 Proviruses Reveals Frequent Asymmetric Long Terminal Repeats. Journal of Virology, 2022, 96, .	3.4	8
5	The Proximal Airway Is a Reservoir for Adaptive Immunologic Memory in Idiopathic Subglottic Stenosis. Laryngoscope, 2021, 131, 610-617.	2.0	12
6	Human leukocyte antigen associations with protection against tuberculosis infection and disease in human immunodeficiency virus-1 infected individuals, despite household tuberculosis exposure and immune suppression. Tuberculosis, 2021, 126, 102023.	1.9	7
7	Comprehensive analysis of TÂcell immunodominance and immunoprevalence of SARS-CoV-2 epitopes in COVID-19 cases. Cell Reports Medicine, 2021, 2, 100204.	6.5	437
8	Subgenomic RNA identification in SARS-CoV-2 genomic sequencing data. Genome Research, 2021, 31, 645-658.	5.5	48
9	Anticytomegalovirus CD4 + T Cells Are Associated With Subclinical Atherosclerosis in Persons With HIV. Arteriosclerosis, Thrombosis, and Vascular Biology, 2021, 41, 1459-1473.	2.4	7
10	Visual Genomics Analysis Studio as a Tool to Analyze Multiomic Data. Frontiers in Genetics, 2021, 12, 642012.	2.3	14
11	The TCR repertoire of α-synuclein-specific T cells in Parkinson's disease is surprisingly diverse. Scientific Reports, 2021, 11, 302.	3.3	26
12	Relationship between CD4 T cell turnover, cellular differentiation and HIV persistence during ART. PLoS Pathogens, 2021, 17, e1009214.	4.7	25
13	Cross-Reactivity to Mutated Viral Immune Targets Can Influence CD8+ T Cell Functionality: An Alternative Viral Adaptation Strategy. Frontiers in Immunology, 2021, 12, 746986.	4.8	3
14	Generation of a Novel SARS-CoV-2 Sub-genomic RNA Due to the R203K/G204R Variant in Nucleocapsid: Homologous Recombination has Potential to Change SARS-CoV-2 at Both Protein and RNA Level. Pathogens and Immunity, 2021, 6, 27-49.	3.1	10
15	Generation of a Novel SARS-CoV-2 Sub-genomic RNA Due to the R203K/G204R Variant in Nucleocapsid: Homologous Recombination has Potential to Change SARS-CoV-2 at Both Protein and RNA Level. Pathogens and Immunity, 2021, 6, 27-49.	3.1	46
16	Severe COVID-19 Is Associated With an Altered Upper Respiratory Tract Microbiome. Frontiers in Cellular and Infection Microbiology, 2021, 11, 781968.	3.9	27
17	Identification of Novel Yellow Fever Class II Epitopes in YF-17D Vaccinees. Viruses, 2020, 12, 1300.	3.3	3
18	High Frequency of Shared Clonotypes in Human T Cell Receptor Repertoires. Cell Reports, 2020, 32, 107882.	6.4	39

#	Article	IF	CITATIONS
19	Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans. Science, 2020, 370, 89-94.	12.6	1,036
20	Identification and Characterization of CD4 ⁺ T Cell Epitopes after Shingrix Vaccination. Journal of Virology, 2020, 94, .	3.4	18
21	Changes in Peripheral and Local Tumor Immunity after Neoadjuvant Chemotherapy Reshape Clinical Outcomes in Patients with Breast Cancer. Clinical Cancer Research, 2020, 26, 5668-5681.	7.0	37
22	T Lymphocyte Subsets Associated With Prevalent Diabetes in Veterans With and Without Human Immunodeficiency Virus. Journal of Infectious Diseases, 2020, 222, 252-262.	4.0	11
23	α-Synuclein-specific T cell reactivity is associated with preclinical and early Parkinson's disease. Nature Communications, 2020, 11, 1875.	12.8	239
24	Characterization of Magnitude and Antigen Specificity of HLA-DP, DQ, and DRB3/4/5 Restricted DENV-Specific CD4+ T Cell Responses. Frontiers in Immunology, 2019, 10, 1568.	4.8	35
25	Single-cell transcriptomics reveal polyclonal memory T-cell responses in skin with positive abacavir patch test results. Journal of Allergy and Clinical Immunology, 2019, 144, 1413-1416.e7.	2.9	19
26	Widespread Tau-Specific CD4 T Cell Reactivity in the General Population. Journal of Immunology, 2019, 203, 84-92.	0.8	36
27	343. T-cell Subsets Associated with Diabetes in Veterans with and without HIV. Open Forum Infectious Diseases, 2019, 6, S182-S183.	0.9	0
28	Clinical and evolutionary consequences of HIV adaptation to HLA. Current Opinion in HIV and AIDS, 2019, 14, 194-204.	3.8	6
29	Deep sequence analysis of HIV adaptation following vertical transmission reveals the impact of immune pressure on the evolution of HIV. PLoS Pathogens, 2019, 15, e1008177.	4.7	14
30	Deconstructing pulmonary fibrosis at singleâ€cell resolution. FASEB Journal, 2019, 33, 847.3.	0.5	0
31	SJS/TEN 2017: Building Multidisciplinary Networks to Drive Science and Translation. Journal of Allergy and Clinical Immunology: in Practice, 2018, 6, 38-69.	3.8	134
32	Sequence-based HLA-A, B, C, DP, DQ, and DR typing of 714 adults from Colombo, Sri Lanka. Human Immunology, 2018, 79, 87-88.	2.4	7
33	Sequence-based HLA-A, B, C, DP, DQ, and DR typing of 159 individuals from the Worcester region of the Western Cape province of South Africa. Human Immunology, 2018, 79, 143-144.	2.4	7
34	Pan-genomic analyses identify key <i>Helicobacter pylori</i> pathogenic loci modified by carcinogenic host microenvironments. Gut, 2018, 67, 1793-1804.	12.1	22
35	Differential Immunodominance Hierarchy of CD8 ⁺ T-Cell Responses in HLA-B*27:05- and -B*27:02-Mediated Control of HIV-1 Infection. Journal of Virology, 2018, 92, .	3.4	14
36	Adipose Tissue is Enriched for Activated and Late-Differentiated CD8+ T Cells and Shows Distinct CD8+ Receptor Usage, Compared With Blood in HIV-Infected Persons. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 77, e14-e21.	2.1	37

#	Article	IF	Citations
37	Sequence-based HLA-A, B, C, DP, DQ, and DR typing of 339 adults from Managua, Nicaragua. Human Immunology, 2018, 79, 1-2.	2.4	8
38	Sequence-based HLA-A, B, C, DP, DQ, and DR typing of 496 adults from San Diego, California, USA. Human Immunology, 2018, 79, 821-822.	2.4	10
39	Urinary Peptides As a Novel Source of T Cell Allergen Epitopes. Frontiers in Immunology, 2018, 9, 886.	4.8	16
40	Evidence of CD4+ T cell-mediated immune pressure on the Hepatitis C virus genome. Scientific Reports, 2018, 8, 7224.	3.3	16
41	Bacterial DNA is present in the fetal intestine and overlaps with that in the placenta in mice. PLoS ONE, 2018, 13, e0197439.	2.5	44
42	Rif1 inhibits replication fork progression and controls DNA copy number in Drosophila. ELife, 2018, 7, .	6.0	40
43	<i>Helicobacter pylori</i> genetic diversification in the Mongolian gerbil model. PeerJ, 2018, 6, e4803.	2.0	12
44	HIV integration sites in latently infected cell lines: evidence of ongoing replication. Retrovirology, 2017, 14, 2.	2.0	59
45	Patterns of Cellular Immunity Associated with Experimental Infection with rDEN2Δ30 (Tonga/74) Support Its Suitability as a Human Dengue Virus Challenge Strain. Journal of Virology, 2017, 91, .	3.4	24
46	Phenome-wide scanning identifies multiple diseases and disease severity phenotypes associated with HLA variants. Science Translational Medicine, $2017, 9, .$	12.4	105
47	T cells from patients with Parkinson's disease recognize α-synuclein peptides. Nature, 2017, 546, 656-661.	27.8	618
48	Sequence-based HLA-A, B, C, DP, DQ, and DR typing of 100 Luo infants from the Boro area of Nyanza Province, Kenya. Human Immunology, 2017, 78, 325-326.	2.4	6
49	Human CD4 ⁺ T Cell Responses to an Attenuated Tetravalent Dengue Vaccine Parallel Those Induced by Natural Infection in Magnitude, HLA Restriction, and Antigen Specificity. Journal of Virology, 2017, 91, .	3.4	83
50	Cytomegalovirus (CMV) Epitope–Specific CD4+ T Cells Are Inflated in HIV+ CMV+ Subjects. Journal of Immunology, 2017, 199, 3187-3201.	0.8	55
51	Prior Dengue Virus Exposure Shapes T Cell Immunity to Zika Virus in Humans. Journal of Virology, 2017, 91, .	3.4	148
52	Shared peptide binding of HLA Class I and II alleles associate with cutaneous nevirapine hypersensitivity and identify novel risk alleles. Scientific Reports, 2017, 7, 8653.	3.3	41
53	Influence of Human Leukocyte Antigen (<scp>HLA</scp>) Alleles and Killer Cell Immunoglobulinâ€Like Receptors (<scp>KIR</scp>) Types on Heparinâ€Induced Thrombocytopenia (<scp>HIT</scp>). Pharmacotherapy, 2017, 37, 1164-1171.	2.6	14
54	Potential for immune-driven viral polymorphisms to compromise antiretroviral-based preexposure prophylaxis for prevention of HIV-1 infection. Aids, 2017, 31, 1935-1943.	2.2	7

#	Article	IF	CITATIONS
55	Global Assessment of Dengue Virus-Specific CD4+ T Cell Responses in Dengue-Endemic Areas. Frontiers in Immunology, 2017, 8, 1309.	4.8	77
56	Definition of Human Epitopes Recognized in Tetanus Toxoid and Development of an Assay Strategy to Detect Ex Vivo Tetanus CD4+ T Cell Responses. PLoS ONE, 2017, 12, e0169086.	2.5	60
57	Comparison of HLA allelic imputation programs. PLoS ONE, 2017, 12, e0172444.	2.5	58
58	HIV-1 Mutation and Recombination Rates Are Different in Macrophages and T-cells. Viruses, 2016, 8, 118.	3.3	9
59	Impact of pre-adapted HIV transmission. Nature Medicine, 2016, 22, 606-613.	30.7	87
60	HLA-DRB1 Alleles Are Associated With Different Magnitudes of Dengue Virus–Specific CD4 ⁺ T-Cell Responses. Journal of Infectious Diseases, 2016, 214, 1117-1124.	4.0	88
61	Primer ID ultra-deep sequencing reveals dynamics of drug resistance-associated variants in breakthrough hepatitis C viruses: relevance to treatment outcome and resistance screening. Antiviral Therapy, 2016, 21, 567-577.	1.0	5
62	Abacavir-Reactive Memory T Cells Are Present in Drug Na \tilde{A} -ve Individuals. PLoS ONE, 2015, 10, e0117160.	2.5	73
63	Acyclovir Has Low but Detectable Influence on HLA-B*57:01 Specificity without Inducing Hypersensitivity. PLoS ONE, 2015, 10, e0124878.	2.5	11
64	Anti-Hepatitis C Virus T-Cell Immunity in the Context of Multiple Exposures to the Virus. PLoS ONE, 2015, 10, e0130420.	2.5	3
65	Polymorphisms of large effect explain the majority of the host genetic contribution to variation of HIV-1 virus load. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 14658-14663.	7.1	154
66	Evolving models of the immunopathogenesis of TÂcellâ€"mediated drug allergy: The role of host, pathogens, and drug response. Journal of Allergy and Clinical Immunology, 2015, 136, 219-234.	2.9	185
67	A general method to eliminate laboratory induced recombinants during massive, parallel sequencing of cDNA library. Virology Journal, 2015, 12, 55.	3.4	14
68	Fibrosing mediastinitis complicating prior histoplasmosis is associated with human leukocyte antigen DQB1*04:02 â´' a case control study. BMC Infectious Diseases, 2015, 15, 206.	2.9	15
69	Helicobacter pylori Adaptation <i>In Vivo</i> in Response to a High-Salt Diet. Infection and Immunity, 2015, 83, 4871-4883.	2.2	19
70	T Cell–Mediated Hypersensitivity Reactions to Drugs. Annual Review of Medicine, 2015, 66, 439-454.	12.2	109
71	Host-Specific Adaptation of HIV-1 Subtype B in the Japanese Population. Journal of Virology, 2014, 88, 4764-4775.	3.4	47
72	HLA class lâ€drugâ€∓â€eell receptor interactions in SJS/TEN. Clinical and Translational Allergy, 2014, 4, P2.	3.2	0

#	Article	IF	Citations
73	Fever, Rash, and Systemic Symptoms: Understanding the Role of Virus and HLA in Severe Cutaneous Drug Allergy. Journal of Allergy and Clinical Immunology: in Practice, 2014, 2, 21-33.	3.8	74
74	Influence of HLA-C Expression Level on HIV Control. Science, 2013, 340, 87-91.	12.6	352
75	Association Study of Common Genetic Variants and HIV-1 Acquisition in 6,300 Infected Cases and 7,200 Controls. PLoS Pathogens, 2013, 9, e1003515.	4.7	109
76	HIV escape mutations occur preferentially at HLA-binding sites of CD8 T-cell epitopes. Aids, 2013, 27, 899-905.	2.2	44
77	Drug hypersensitivity caused by alteration of the MHC-presented self-peptide repertoire. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 9959-9964.	7.1	354
78	Correlates of Protective Cellular Immunity Revealed by Analysis of Population-Level Immune Escape Pathways in HIV-1. Journal of Virology, 2012, 86, 13202-13216.	3.4	99
79	Highâ€avidity, highâ€IFNγâ€producing CD8 Tâ€cell responses following immune selection during HIVâ€1 infectio Immunology and Cell Biology, 2012, 90, 224-234.	n 2.3	36
80	HLA and pharmacogenetics of drug hypersensitivity. Pharmacogenomics, 2012, 13, 1285-1306.	1.3	161
81	The structural basis of <scp>HLA</scp> â€associated drug hypersensitivity syndromes. Immunological Reviews, 2012, 250, 158-166.	6.0	31
82	Complications resulting from antiretroviral therapy for HIV infection., 2012, , 177-191.		0
83	Extensive HLA-driven viral diversity following a narrow-source HIV-1 outbreak in rural China. Blood, 2011, 118, 98-106.	1.4	36
84	Mapping the Landscape of Host-Pathogen Coevolution: HLA Class I Binding and Its Relationship with Evolutionary Conservation in Human and Viral Proteins. Journal of Virology, 2011, 85, 1310-1321.	3.4	62
85	Translation of HLA–HIV Associations to the Cellular Level: HIV Adapts To Inflate CD8 T Cell Responses against Nef and HLA-Adapted Variant Epitopes. Journal of Immunology, 2011, 187, 2502-2513.	0.8	25
86	Adaptive Interactions between HLA and HIV-1: Highly Divergent Selection Imposed by HLA Class I Molecules with Common Supertype Motifs. Journal of Immunology, 2010, 184, 4368-4377.	0.8	39
87	Common Genetic Variation and the Control of HIV-1 in Humans. PLoS Genetics, 2009, 5, e1000791.	3.5	377
88	Divergent adaptation of hepatitis C virus genotypes 1 and 3 to human leukocyte antigen-restricted immune pressure. Hepatology, 2009, 50, 1017-1029.	7.3	60
89	Adaptation of HIV-1 to human leukocyte antigen class I. Nature, 2009, 458, 641-645.	27.8	408
90	Unique features of HLA-mediated HIV evolution in a Mexican cohort: a comparative study. Retrovirology, 2009, 6, 72.	2.0	33

#	Article	IF	Citations
91	Successful Translation of Pharmacogenetics into the Clinic. Molecular Diagnosis and Therapy, 2009, 13, 1-9.	3.8	101
92	HLA-Associated Immune Escape Pathways in HIV-1 Subtype B Gag, Pol and Nef Proteins. PLoS ONE, 2009, 4, e6687.	2.5	148
93	HLA-B*5701 Screening for Hypersensitivity to Abacavir. New England Journal of Medicine, 2008, 358, 568-579.	27.0	1,665
94	Human Leukocyte Antigen Class I-Restricted Activation of CD8+ T Cells Provides the Immunogenetic Basis of a Systemic Drug Hypersensitivity. Immunity, 2008, 28, 822-832.	14.3	309
95	Marked Epitope- and Allele-Specific Differences in Rates of Mutation in Human Immunodeficiency Type 1 (HIV-1) Gag, Pol, and Nef Cytotoxic T-Lymphocyte Epitopes in Acute/Early HIV-1 Infection. Journal of Virology, 2008, 82, 9216-9227.	3.4	162
96	High Sensitivity of Human Leukocyte Antigen–B*5701 as a Marker for Immunologically Confirmed Abacavir Hypersensitivity in White and Black Patients. Clinical Infectious Diseases, 2008, 46, 1111-1118.	5.8	384
97	Cytokine Profiling in Abacavir Hypersensitivity Patients. Antiviral Therapy, 2008, 13, 281-288.	1.0	22
98	Refining Abacavir Hypersensitivity Diagnoses using a Structured Clinical Assessment and Genetic Testing in the Swiss HIV Cohort Study. Antiviral Therapy, 2008, 13, 1019-1028.	1.0	29
99	Skewed association of polyfunctional antigen-specific CD8 T cell populations with HLA-B genotype. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 16233-16238.	7.1	118
100	HLA-B*5701 screening for susceptibility to abacavir hypersensitivity. Journal of Antimicrobial Chemotherapy, 2007, 59, 591-593.	3.0	61
101	Abacavir Hypersensitivity. , 2007, , 95-104.		1
102	Founder Effects in the Assessment of HIV Polymorphisms and HLA Allele Associations. Science, 2007, 315, 1583-1586.	12.6	234
103	Drug hypersensitivity in HIV. Current Opinion in Allergy and Clinical Immunology, 2007, 7, 324-330.	2.3	91
104	Immune responses to abacavir in antigen-presenting cells from hypersensitive patients. Aids, 2007, 21, 1233-1244.	2.2	48
105	A Whole-Genome Association Study of Major Determinants for Host Control of HIV-1. Science, 2007, 317, 944-947.	12.6	1,136
106	Extensive HLA class I allele promiscuity among viral CTL epitopes. European Journal of Immunology, 2007, 37, 2419-2433.	2.9	120
107	Leveraging Hierarchical Population Structure in Discrete Association Studies. PLoS ONE, 2007, 2, e591.	2.5	33
108	External Quality Assessment of <i>HLA-B*5701</i> Reporting: An International Multicentre Survey. Antiviral Therapy, 2007, 12, 1027-1032.	1.0	40

#	Article	IF	CITATIONS
109	Prospective Genetic Screening Decreases the Incidence of Abacavir Hypersensitivity Reactions in the Western Australian HIV Cohort Study. Clinical Infectious Diseases, 2006, 43, 99-102.	5.8	301
110	Host genetics unplugged: removing the camouflage of viral adaptation. Current Opinion in HIV and AIDS, 2006, 1, 218-219.	3.8	0
111	A sensitive and rapid alternative to HLA typing as a genetic screening test for abacavir hypersensitivity syndrome. Pharmacogenetics and Genomics, 2006, 16, 353-357.	1.5	47
112	Control of human immunodeficiency virus replication by cytotoxic T lymphocytes targeting subdominant epitopes. Nature Immunology, 2006, 7, 173-178.	14.5	209
113	Host genetics and viral infections: immunology taught by viruses, virology taught by the immune system. Current Opinion in Immunology, 2006, 18, 413-421.	5.5	19
114	Predicting and diagnosing abacavir and nevirapine drug hypersensitivity: from bedside to bench and back again. Pharmacogenomics, 2006, 7, 15-23.	1.3	20
115	Impact of HLA-B Alleles, Epitope Binding Affinity, Functional Avidity, and Viral Coinfection on the Immunodominance of Virus-Specific CTL Responses. Journal of Immunology, 2006, 176, 4094-4101.	0.8	150
116	Transmission and accumulation of CTL escape variants drive negative associations between HIV polymorphisms and HLA. Journal of Experimental Medicine, 2005, 201, 891-902.	8.5	220
117	HIV/AIDS: HIV: Experiencing the Pressures of Modern Life. Science, 2005, 307, 1422-1424.	12.6	9
118	Adverse effects of antiretroviral therapy for HIV infection: a review of selected topics. Expert Opinion on Drug Safety, 2005, 4, 201-218.	2.4	43
119	HIV-1 Viral Escape in Infancy Followed by Emergence of a Variant-Specific CTL Response. Journal of Immunology, 2005, 174, 7524-7530.	0.8	109
120	Antiretroviral-therapy-associated lipoatrophy: current status and future directions. Sexual Health, 2005, 2, 153.	0.9	39
121	Pharmacogenetics of antiretroviral therapy: genetic variation of response and toxicity. Pharmacogenomics, 2004, 5, 643-655.	1.3	33
122	Impact of host genetics on HIV disease progression and treatment. Aids, 2004, 18, 1231-1240.	2.2	20
123	Dominant influence of HLA-B in mediating the potential co-evolution of HIV and HLA. Nature, 2004, 432, 769-775.	27.8	784
124	Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 4180-4185.	7.1	451
125	Complications Associated with Nrti Therapy: Update on Clinical Features and Possible Pathogenic Mechanisms. Antiviral Therapy, 2004, 9, 849-863.	1.0	83
126	Contribution of Nucleoside-Analogue Reverse Transcriptase Inhibitor Therapy to Lipoatrophy from the Population to the Cellular Level. Antiviral Therapy, 2003, 8, 617-626.	1.0	101

SIMON MALLAL

#	Article	IF	CITATIONS
127	Antiretoviral Therapy and the Lipodystrophy Syndrome, Part 2: Concepts in Aetiopathogenesis. Antiviral Therapy, 2001, 6, 145-160.	1.0	54
128	The genetic basis for the association of the 8.1 ancestral haplotype (A1, B8, DR3) with multiple immunopathological diseases. Immunological Reviews, 1999, 167, 257-274.	6.0	506
129	Positive Selection of Mutations in the Helicobacter pylori <i>katA</i> 5′ Untranslated Region in a Mongolian Gerbil Model of Gastric Disease. Infection and Immunity, 0, , .	2.2	3